|
|
British Journal of Cancer (2007) 96, 1353-1357.
doi:10.1038/sj.bjc.6603735 www.bjcancer.com Published online 17 April 2007
Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer
H Shinchi1, K Maemura1, H Noma1, Y Mataki1, T Aikou1 and S Takao2
1Department of Surgical Oncology and Digestive Surgery, Kagoshima University, Kagoshima, Japan
2Frontier Science Research Center, Kagoshima University, Kagoshima, Japan
Correspondence to: Dr H Shinchi, E-mail: shinchi@m.kufm.kagoshima-u.ac.jp
Received 29 August 2006; revised 15 March 2007; accepted 19 March 2007; published online 17 April 2007
In this phase-I trial, we evaluated the safety of S-1, a novel oral fluoropyrimidine anticancer agent, combined with external-beam radiotherapy (EBRT) to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) in unresectable pancreatic cancer patients. Patients had histologically proven unresectable locally advanced or metastatic pancreatic cancer. S-1 was administered orally twice daily. External-beam radiotherapy was delivered in fractions of 1.25 Gy ´ 2 per day, totalling 50 Gy per 40 fractions for 4 weeks. S-1 was given at five dose levels: 60 mg m-2 day-1 on days 1-7 and 15-21 (level 1), 1-14 (level 2), and 1-21 (level 3a) and 80 mg m-2 day-1 on days 1-21 (level 3b) and 1-28 (level 4). We studied 17 patients: dose levels 1 (four patients), 2 (four patients), 3a (three patients), 3b (three patients), and 4 (three patients). One patient in level 1 (grade 3 vomiting) and two patients in level 4 (grade 4 neutropenia and grade 3 anorexia) showed DLT. No DLT was seen for levels 2, 3a, and 3b. Clinical effects by computed tomography included 5 partial responses (35%), 11 cases of stable disease, and one case of progressive disease. CA19-9 levels of less than half the starting values were observed in 8 of 16 (50%) patients. S-1 at a dose of 80 mg m-2 day-1 given on days 1-21 is safe and recommended for phase-II study in patients with locally advanced and unresectable pancreatic cancer when given with EBRT.
Keywords: phase-I study; S-1; pancreatic cancer; chemoradiation
back to top  |
| Article links | |
| ||
| ||
 | Send to a friend | |
 | Download PDF | |
| ||
| ||
| ||
 | Full text | |
| ||
| ||
| ||
 | Preceding article | |
 | Next article | |
 | Table of Contents | |
| ||
| ||
| ||
| ||
| ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2007 Cancer Research UK | ||
| |||
| Privacy Policy | |||